10:55 AM EDT, 09/17/2024 (MT Newswires) -- Biogen (BIIB) said Tuesday its new drug submission for omaveloxolone to treat Friedreich's ataxia in adults and adolescents aged 16 years and above was accepted for priority review by Health Canada.

A regulatory decision on the submission is expected early next year, the company said.

Friedreich's ataxia is a life-shortening neuromuscular disease.

Biogen shares were up nearly 1% in recent trading.

Price: 201.17, Change: +1.59, Percent Change: +0.80